The ATXN1L Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This product features targeted disruption of the ATXN1L gene, generating a loss-of-function model to investigate ATXN1L-dependent transcriptional regulation and its contributions to cancer and neurodegenerative disease biology.
A-549 cells are a well-characterized model of human lung adenocarcinoma, originally isolated from a 58-year-old male patient. These adherent epithelial cells retain key features of alveolar type II pneumocytes and are extensively employed to study respiratory epithelial biology, oncogenic signaling cascades, and therapeutic responses, making them a physiologically relevant background for gene perturbation experiments.
ATXN1L encodes a chromatin-binding transcriptional coregulator that forms repressor or activator complexes with the transcription factor CIC (Capicua). Through these interactions, ATXN1L modulates the expression of downstream targets, including genes regulated by ETS transcription factors, and integrates signals from the Notch, Wnt, and TGF-beta pathways. Upstream, ATXN1L is influenced by growth factor signaling and the MAPK/ERK pathway, and its activity is further shaped by associations with ATXN1, histone deacetylases, and RNA-binding proteins, thereby coordinating gene networks that control cell proliferation and differentiation.
Disruption of ATXN1L in A-549 cells enables dissection of its role in transcriptional programs that drive lung adenocarcinoma progression. Given ATXN1L??s involvement in CIC-mediated repression, its loss may alter the expression of genes governing cell cycle progression, apoptosis, and epithelial-mesenchymal transition??processes critical for tumor growth and metastasis. This knockout model thus offers a valuable system to examine how ATXN1L-dependent regulatory circuits intersect with oncogenic pathways in a disease-relevant cellular context.
This polyclonal knockout cell population is suited for a range of functional genomics applications, including RNA-seq and ChIP-seq to map global transcriptional and chromatin alterations, and RT-qPCR or Western blotting for targeted validation. Downstream phenotypic characterization can be performed using proliferation, apoptosis, cell cycle, and flow cytometry assays. Research applications extend to drug target validation, particularly in assessing ATXN1L as a modulator of therapeutic response in lung cancer, as well as comparative studies in neurodegenerative disease models where the ATXN1L paralog ATXN1 is implicated. For additional information, please contact Ascent Research.
